Filtration devices and methods related thereto
US-2023225850-A1 · Jul 20, 2023 · US
US11071812B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11071812-B2 |
| Application number | US-201715608023-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 30, 2017 |
| Priority date | May 31, 2016 |
| Publication date | Jul 27, 2021 |
| Grant date | Jul 27, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Doxorubicin is extracted from blood using anionic material, such as a resin comprising sulfonated polystyrene divinylbenzene beads, and polyethersulfone membrane, or both. After exposing the resin and/or membrane to blood in order to remove doxorubicin therefrom, the doxorubicin maybe extracted from the resin and/or membrane by exposing the material to an extraction solution, sonicating the extraction solution to enhance release of the doxorubicin, and repeating the exposure and sonication in order to remove substantially all of doxorubicin from the resin.
Opening claim text (preview).
What is claimed is: 1. A method for measuring doxorubicin present in a patient's blood, said method comprising: mixing a sample of the patient's blood with a silver nitrate solution; adding a volume of methanol to the mixture; further mixing the blood, silver nitrate, and methanol together for at least 10 seconds; letting the mixed blood, silver nitrate, and methanol stand for at least 30 minutes to precipitate particles and form a supernatant; separating the supernatant via chromatography, wherein the separated supernatant contains doxorubicin originally present in the blood sample; and analyzing the separated supernatant via spectroscopy, wherein the UV absorbance of doxorubicin is measured. 2. The method of claim 1 , including the step of analyzing the separated supernatant via spectroscopy at 254 nm. 3. The method of claim 1 , including the step of analyzing the separated supernatant via spectroscopy at 480 nm. 4. The method of claim 1 , wherein a chromatography buffer comprises acetonitrile and NaH 2 PO 4 . 5. The method of claim 1 , wherein the total mixed volume of the sample of the patient's blood with the silver nitrate solution is below 200 μl. 6. The method of claim 1 , wherein the volume of methanol added to the mixture is less than or equal to 1 ml.
Cation exchangers for chromatographic processes · CPC title
by absorption (A61M1/3675 takes precedence) · CPC title
Processes using organic exchangers · CPC title
Cleaning blood contaminated by local chemotherapy of a body part temporarily isolated from the blood circuit · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.